Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Clin Breast Cancer
; 24(3): 163-174, 2024 04.
Article
en En
| MEDLINE
| ID: mdl-38341370
ABSTRACT
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Inmunoconjugados
/
Neoplasias de la Mama Triple Negativas
/
Antineoplásicos
Idioma:
En
Revista:
Clin Breast Cancer
/
Clin. breast cancer
/
Clinical Breast Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article